Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in ...

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking an ...

Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase.

Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...

And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...

Embryo-Fetal Toxicity ZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during p ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

The U.S. Food AND Drug Administration (FDA) has granted accelerated approval of a new drug for treating bilary tract cancer ...

Jazz Pharmaceuticals says the U.S. Food and Drug Administration has approved use of the tumor-fighting antibody to treat adults with a form of biliary-tract cancer (BTC) ...